Pay in 4 interest-free payments of $5.21 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Tirzepatide (dual GLP-1/GIP receptor agonist): In the SURMOUNT-1 trial, participants on the highest tirzepatide dose (15 mg) achieved approximately 22.5% body weight reduction at 72 weeks
Forms with generally good tolerability include: Magnesium glycinate : Chelated to the amino acid glycine, this form demonstrates good absorption and minimal laxative effect, making it potentially suitable for GLP-1 users already experiencing gastrointestinal symptoms
Do not self-administer unless instructed to do so by a medical professional
The additional weight loss from dual GIP/GLP-1 agonism (vs
Tirzepatide is not just about losing weight
US$ 20.12
US$ 20.43
US$ 25.24
US$ 21.87
